Theravance Biopharma Investigational Site
Manchester, M23 9QZ, United Kingdom
NCT Number: NCT04350736
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 1
Manchester, M23 9QZ, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Study drug to be administered by inhalation
Placebo to be administered by inhalation
Time frame: Day 1 to Day 8
Number and severity of treatment emergent adverse events
Time frame: Day 1 to Day 14
Number and severity of treatment emergent adverse events
Time frame: Day 1 through Day 4
Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)
Time frame: Day 1 through Day 4
Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Maximum observed concentration (Cmax)
Time frame: Day 1 through Day 4
Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)
Time frame: Day 1 through Day 9
Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)
Time frame: Day 1 through Day 9
Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Maximum observed concentration (Cmax)
Time frame: Day 1 through Day 9
Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)
Theravance Biopharma
Industry
A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04402866
Acute Lung Injury, Acute Lung Injury (ALI) Associated With COVID-19
Duarte, California, United States
View Trial DetailsNCT07397156
ARDS (Acute Respiratory Distress Syndrome), Acute Lung Injury
Zielona Góra, Lubusz Voivodeship, Poland
View Trial DetailsNCT06997666
ARDS (Acute Respiratory Distress Syndrome), Acute Lung Injury
Diyarbakır, Turkey (Türkiye)
View Trial DetailsNCT04871893
Acute Kidney Injury, Acute Lung Injury
Erlangen, Bavaria, Germany
View Trial Details